TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

Oncotarget 2017 Apr;8(14):23061-23072

Department of Laboratory Medicine, Medical University of Vienna, Austria.

In chronic myeloid leukemia (CML) resistance against one or more BCR-ABL1 tyrosine kinase inhibitors (TKI) remains a clinical challenge. Preclinical data suggest that TKI combinations may overcome resistance. We report on a heavily pre-treated 78 year-old female patient with CML who developed multi-resistant blast crisis with bone marrow fibrosis and a Ph- clone. Treatment with ponatinib resulted in blast cell clearance, decrease in fibrosis, and disappearance of BCR-ABL1, but also in severe thrombocytopenia with bleedings requiring platelet transfusions. We therefore switched from ponatinib to bosutinib. During bosutinib, platelet counts recovered. However, after 6 months, BCR-ABL1 mRNA levels increased to > 1%. Therefore, we ´switched back´ to ponatinib, and this was again followed by disappearance of BCR-ABL1 and a decrease in platelets. During the next 2 years, we applied ponatinib and bosutinib in continuous rotation-cycles and added hydroxyurea in order to suppress all sub-clones and to balance between efficacy and potential side effects following the principle of personalized medicine. With this approach the patient remained in complete molecular response and reached normal blood counts and a normal quality of life without vascular or other side effects. In conclusion, TKI rotation is a novel potent approach to suppress multiple resistant sub-clones and to balance between clinical efficacy and side effects in patients with advanced CML. Clinical trials are now warranted to show that TKI-rotation is in general safe and effective in these patients.

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410285PMC
April 2017
32 Reads

Publication Analysis

Top Keywords

side effects
12
blast crisis
8
molecular response
8
multi-resistant blast
8
sub-clones balance
8
disappearance bcr-abl1
8
ponatinib bosutinib
8
clearance decrease
4
decrease fibrosis
4
remained complete
4
patient remained
4
fibrosis disappearance
4
bcr-abl1 severe
4
bleedings requiring
4
personalized medicine
4
requiring platelet
4
thrombocytopenia bleedings
4
medicine approach
4
approach patient
4
severe thrombocytopenia
4

Similar Publications